This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Coverage Policy

PROLOGUE

Prescription Drug Coverage Policy

PROLOGUE: In recent years the halls of Congress have increasingly served as the battlefield upon which consumer groups and the U.S. pharmaceutical industry have waged war for control of public opinion with respect to high drug prices and access to the latest technologies. Industry has consistently justified high prices by pointing to research and development (R&D) costs, while consumer groups have countered that drug companies spend more on marketing, advertising, and executive compensation than on R&D. A July 2001 report by Families USA, for example, found that of the nine U.S. companies that manufactured the fifty top-selling drugs for the . . . [Full Text of this Article]

                      What's this?